Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00713609 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne

A Phase 2 study of Acne Vulgaris, sponsored by Stiefel, a GSK Company.

Completed
Registry status
Phase 2
Development phase
591
Enrollment target
16
Study locations

NCT00713609 is a Phase 2 study of Acne Vulgaris that has completed, run by Stiefel, a GSK Company. The registered enrollment target is 591 participants, above the 267-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (121% higher). The trial reports 16 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00713609, a Phase 2 study of Acne Vulgaris, has completed, sponsored by Stiefel, a GSK Company.

COMPLETED
Registry status
Phase 2
Development phase
591 participants
Enrollment target
16
Study locations

Study Summary

Benzoyl peroxide, clindamycin and tazarotene are known to be effective treatment alternative for acne vulgaris. The purpose of this study is to assess the safety and efficacy of a combination product including these actives for the treatment of acne vulgaris. You may be suitable to take part in this study because you have acne vulgaris on your face. Acne vulgaris usually affects the face, but it can also affect the skin on the chest, arms, legs, and back.

Conditions Studied

Acne Vulgaris

Interventions

  • DRUG Vehicle cream
  • DRUG Vehicle gel
  • DRUG Benzoyl peroxide gel
  • DRUG Clindamycin gel
  • DRUG Tazarotene cream

Study Locations (16)

Texas

  • Dermatology Treatment & Research Center - Dallas
  • Suzanne Bruce and Associates, PA - Houston
  • Dermatology Clinical Research Center of San Antonio - San Antonio

California

  • Center for Dermatology Cosmetic and Laser Surgery - Fremont
  • Center for Dermatology and Laser Surgery - Sacramento

North Carolina

  • University of North Carolina Chapel Hill - Chapel Hill
  • Dermatology Consulting Services - High Point

Tennessee

  • Rivergate Dermatology & Skin Care Center - Goodlettsville
  • The Skin Wellness Center, PC - Knoxville

Arkansas

  • Dermatology Research of Arkansas - Little Rock

Colorado

  • Boulder Medical Center, P.C. - Boulder

Florida

  • Dermatology Associates Research - Coral Gables

Georgia

  • MedaPhase, Inc. - Newnan

Trial Details

FieldValue
Enrollment Target 591 participants
Start Date 2008-06
Est. Completion 2009-03
Phase Phase 2

Sponsor

Stiefel, a GSK Company

37 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00713609

The ClinicalTrials.gov registry entry for NCT00713609 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 591 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 267-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (121% higher). The listed sponsor is Stiefel, a GSK Company, which has 37 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 5 interventions - of which Vehicle cream is the first listed.

NCT00713609 reports 16 study locations spanning 11 distinct geographic areas - top geographies include Texas, California, North Carolina.

Frequently Asked Questions

What is clinical trial NCT00713609 about?

NCT00713609 is a clinical study titled "Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne". Benzoyl peroxide, clindamycin and tazarotene are known to be effective treatment alternative for acne vulgaris. The purpose of this study is to assess the safety and efficacy of a combination product including these actives for the treatment of acne vulgaris. You may be suitable to take part in thi...

What is the current status of trial NCT00713609?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 591 participants. The study started on 2008-06. Estimated completion is 2009-03.

What conditions does trial NCT00713609 study?

This clinical trial studies the following conditions: Acne Vulgaris.

What interventions are being tested in trial NCT00713609?

The interventions under investigation include: Vehicle cream (DRUG), Vehicle gel (DRUG), Benzoyl peroxide gel (DRUG), Clindamycin gel (DRUG), Tazarotene cream (DRUG).

Who is sponsoring clinical trial NCT00713609?

This trial is sponsored by Stiefel, a GSK Company, which has 37 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00713609 being conducted?

This trial has 16 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acne Vulgaris

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acne Vulgaris

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.